ArticleHealthcare (Basel, Switzerland)2024
Long-Term Bone Density Changes and Fracture Risk in Myasthenia Gravis: Implications for FRAX
Article in Healthcare (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Prevalence and predictors of low bone mineral density in Myasthenia gravis.Arquivos de neuro-psiquiatria · 2026Article
- Fracture Occurrence Within FRAX-Defined High-Risk Myasthenia Gravis: An Exploratory Stratification by Age and Activities of Daily Living.Journal of clinical medicine · 2026Article
- Osteoporosis knowledge and health beliefs in ındividuals with myasthenia gravis: a cross-sectional controlled study.Revista da Associacao Medica Brasileira (1992) · 2026Article
- Functional Status Enhances the FRAXJournal of clinical medicine · 2025Article
- Disease burden of myasthenia gravis in relation to oral corticosteroid dose: an insurance claims database study in Japan.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) patients often require long-term glucocorticoid therapy, which may affect bone health. This study aimed to assess long-term changes in bone mineral density (BMD), evaluate osteoporotic fracture incidence, and examine the relationship between MG-specific factors and bone health outcomes over a 10-year period. This single-center, prospective cohort study included 28 MG patients. BMD, T-scores, Z-scores, and bone turnover markers were measured at baseline. FRAX
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.